Skip to main content
Clinical Trials/NCT02955537
NCT02955537CompletedNot Applicable

MI-BP: mHealth to Improve Blood Pressure Control

University of Michigan2 sites in 1 country162 target enrollmentStarted: January 11, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
162
Locations
2
Primary Endpoint
Change in mean systolic blood pressure

Study Overview

Brief Summary

This study seeks to evaluate a multicomponent mobile intervention to change multiple hypertension-related health behaviors in minorities and the underserved with uncontrolled hypertension. Half of the participants will receive a mobile intervention designed to improve physical activity, sodium intake, and medication adherence. The other half will receive usual care.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
25 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Detroit-area residents
  • •Hypertensive
  • •Owning a compatible smartphone
  • •Presenting to the Detroit Medical Center Detroit Receiving, Sinai-Grace Hospital, or selected Community Health Screening Events with, but not necessarily for, uncontrolled blood pressure (systolic blood pressure ≥ 135 mm Hg at triage and on repeat measurement using the BpTRU device).

Exclusion Criteria

  • •No self-reported prior history of hypertension
  • •No hypertension diagnosis documented in their medical record
  • •Non-English speaking
  • •Presenting with an acute illness necessitating immediate medical intervention
  • •Presenting with an admission to the hospital for critical reasons (as determined by the attending physician)
  • •Pregnant (as determined by a dip test at screening), or self-report during trial.
  • •Having the following serious comorbidities or confounders due to the fact that they may make blood pressure control difficult or necessitate frequent Emergency Department use or hospitalization:
  • •Previous diagnosis of resistant hypertension (or current use of 3 or more maximally dosed antihypertensive agents without achievement of blood pressure control)
  • •Steroid dependent asthma or emphysema
  • •Cirrhosis or hepatic failure
  • •Chronic heart failure (any stage)
  • •Previous diagnosis of acute myocardial infarction, angina (stable or unstable), or known coronary artery disease
  • •Previous diagnosis of cerebrovascular disease (including transient ischemic attack or stroke)
  • •Known valvular heart disease
  • •Stage IV or V chronic kidney disease
  • •Cancer (terminal or undergoing active chemotherapeutic or radiation therapy)
  • •Patients with other serious medical conditions that may affect their ability to self-monitor blood pressure (such a dementia)
  • •Having a history of alcohol or drug abuse as determined by the CAGE-AID questionnaire (excluded if 2 or more)
  • •Week 2 measurement of systolic blood pressure < 130 mm Hg using the BpTRU device or study-issued BP cuff.

Arms & Interventions

Usual care

No Intervention

Usual care participants will be given a prescription for antihypertensive medications, printed educational materials on hypertension, and a home blood pressure monitor for daily use, but will receive no further intervention.

MI-BP

Experimental

MI-BP participants will receive an antihypertensive medication prescription, and be asked to use technology-mediated devices/services linked to positive changes in target behavior/outcome including the MI-BP app, a secure, mHealth platform that will be installed on participant smartphones.

Intervention: MI-BP (Other)

Outcomes

Primary Outcomes

Change in mean systolic blood pressure

Time Frame: from baseline to 1 year

Secondary Outcomes

  • Change in physical activity as measured by the International Physical Activity Questionnaire (IPAQ-SF)(from baseline to 1 year)
  • Change in sodium intake as measured by the Block Sodium Screener(from baseline to 1 year)
  • Change in medication adherence as measured by Adherence to Refills and Medications Scale (ARMS)(from baseline to 1 year)
  • Change in blood pressure control(from baseline to 1 year)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Lorraine Buis

Associate Professor of Family Medicine, Medical School and Associate Professor of Information, School of Information

University of Michigan

Study Sites (2)

Loading locations...

Similar Trials